Trials / Completed
CompletedNCT00534248
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 22,439 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 50 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Zoster Vaccine, Live (Zostavax™) | A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1. |
| BIOLOGICAL | Comparator: Placebo | A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1. |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2007-09-24
- Last updated
- 2017-04-12
- Results posted
- 2011-05-02
Source: ClinicalTrials.gov record NCT00534248. Inclusion in this directory is not an endorsement.